A phase II trial evaluating the treatment of the diabetic medication, Liraglutide, as a potential new treatment for patients with mild to moderate Alzheimer’s disease.
Read MoreImperial College Memory Research Centre
Professor Edison is the Professor of Neuroscience and Clinical Professor in the Division of Neurology, Faculty of Medicine at Imperial College London. He is a consultant at Imperial College Healthcare NHS trust - Hammersmith Hospital, St Mary’s Hospital and Charing Cross Hospital”. He is also an honorary Professor at Cardiff University.
Prof Edison’s research has focused on neuroimaging with novel molecular probes using PET and magnetic resonance techniques for imaging pathophysiological changes associated with Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative diseases. He has extensive experience in PET imaging in different neurodegenerative and neuroinflammatory conditions. Combined with his clinical expertise in different types of degenerative diseases and dementia, he has investigated the relationship between amyloid deposition, microglial activation, and glucose metabolism in various disorders, along with evaluating different transporters in the brain. His work in assessing microglial activation and amyloid load showed that both of these are increased in Alzheimer’s disease, and that microglial activation correlates with cognition, while amyloid load does not correlate with cognition. He was a HEFCE Clinical Senior Lecturer before he became a Professor of Neuroscience.
His work now focuses on neuroinflammation and the interplay between inflammation and immunity in neurodegenerative and neuroinflammatory disease, and relating these with genetic information. He is also evaluating methods of modulating inflammation and amyloid in Alzheimer’s disease, and the influence of cardiometabolic factors on the development of neurodegenerative diseases by means of clinical and preclinical studies.
He leads the Imperial College Memory Research Centre, and is the Chief Investigator of several imaging studies using PET and MRI, and heads multicentre studies evaluating novel treatment of Alzheimer's and other neurodegenerative diseases. He also runs a memory clinic at Imperial College Healthcare NHS Trust.
Our Current Studies
Neuro inflammation and Amyloid Study
Investigating the relationship between inflammation and amyloid in the brains of patients with mild cognitive impairment and Alzheimer’s disease.
Read MoreMicroglial Activation in Alzheimer’s Disease and Mild Cognitive Impairment
Investigating the relationship between inflammation and amyloid in the brains of patients with mild cognitive impairment and Alzheimer’s disease using a novel tracer.
Read MoreAstroglial Activation, β-amyloid Deposition and Neuronal Activity in AD
Investigating the relationship between astroglia and amyloid in the brains of people with Alzheimer’s disease and mild cognitive impairment, and how this affects thinking and memory using a novel astroglial activation imaging marker.
Read MoreSurgery and Neuroinflammation
A study looking at the relationship between inflammation in the brain and obesity in patient’s undergoing gastric bypass surgery. This study involves a PET and MRI scan prior to the surgery, and then again 6 months after the surgery.
Read MoreUptake and Kinetics of [18F]ICMT11
Evaluating brain changes seen in some Alzheimer’s disease patients (protein build-up and specific proteins activity in the brain).
Read MoreTake part in a study
We are looking for people with mild memory problems, Alzheimer’s disease, and healthy volunteers.
If you are interested in taking part, please contact us by using our e-mail: memory@imperial.ac.uk or by telephone 0208 383 3704 or by sending us a message by using the contact us form.
Please include your age, name and contact details and a brief description of the enquiry / study.
Have a question? ...Please check our “Frequently Asked Questions”
OUR LATEST NEWS
This article looks into progressive loss of neurons in the brain, which is one of the main processes in dementia and age-related cognitive impairment. This can be detected with current biomarker tests.
Read MoreAn exciting new stage is iminent for the patients who wish to continue after completing the ELAD trial of the anti-diabetic drug, liraglutide, in patients with Alzheimer’s disease.
Read MoreSeveral trials have investigated the use of anti-amyloid therapies in Alzheimer’s disease, but these have all had disappointing results.
Read More